IN8bio to Present at TD Cowen 45th Annual Health Care Conference: A Glimpse into the Future of Gamma-Delta T Cell Therapies

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, has announced that William Ho, CEO and co-founder, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. The presentation will provide an update on the company's progress, pipeline, and future prospects. A live webcast and replay will be available on the IN8bio website under "Events and Presentations" in the News & Presentations section.

IN8bio's lead program, INB-400, is a Phase 2 clinical trial for glioblastoma (GBM), a type of brain cancer with a high unmet medical need. The company's other programs include Phase 1 trials for solid and hematologic tumors, such as INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. IN8bio's DeltEx platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop cell therapies designed to effectively identify and eradicate tumor cells.

The upcoming presentation at the TD Cowen 45th Annual Health Care Conference is an opportunity for IN8bio to showcase its progress and engage with investors, analysts, and key opinion leaders in the biopharmaceutical industry. The conference provides a platform for companies to share their stories, discuss their pipelines, and address questions from the investment community. This event is particularly important for IN8bio, as it allows the company to build awareness, reputation, and relationships with potential investors and partners.

Investors can expect updates on IN8bio's clinical trials, regulatory progress, and strategic initiatives during the presentation. The company may also provide insights into its plans for expanding its clinical trials and pipeline, as well as any collaborations or partnerships that could enhance its position in the competitive landscape. Additionally, IN8bio may discuss its financial performance and outlook, providing investors with a better understanding of the company's growth prospects and potential value.

In conclusion, IN8bio's presentation at the TD Cowen 45th Annual Health Care Conference is an important milestone for the company, as it provides an opportunity to share its progress, engage with stakeholders, and build its reputation in the biopharmaceutical industry. Investors can look forward to learning more about IN8bio's innovative gamma-delta T cell therapies and the company's potential to revolutionize cancer treatment.